Sunitinib: A multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies

BioDrugs

Volumn 23, Issue 6, 2009, Pages 377-389

  Papaetis, Georgios S ^a   Syrigos, Kostas N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; PEGINTERFERON; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SU 012487; SU 012662; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IN VITRO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MACROPHAGE; MOLECULAR THERAPY; MOUTH CAVITY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VASCULARIZATION;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; INDOLES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 70450197345     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11318860-000000000-00000     Document Type: Review

References (123)

1. Syrigos KN, Harrington KJ. Targeted therapy for cancer. Oxford: Oxford University Press, 2002 Oct
2. Papaetis GS, Roussos C, Syrigos KN. Targeted therapies for non-small cell lung cancer. Curr Pharm Des 2007; 13: 2810-2831
3. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol 2005; 45: 357-384
4. Charpidou A, Blatza D, Anagnostou E, et al. Review: EGFR mutations in non-small cell lung cancer - clinical implications. In Vivo 2008; 22: 529-536
5. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286 (Pubitemid 46505878)
6. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186
7. Bergers G, Benjamin LE. Tumourigenesis and the angiogenic switch. Cancer Nat Rev 2003; 3: 401-410
8. Senger Dr, Galli Sj, Drovak AM, et al. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985
9. Drovak HF, Brown LF, Detmar M, et al. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039
10. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumour surgery. Ann Surg 2002; 236: 37-42
11. Karayiannakis AJ, Bolanaki H, SyrigosKN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003; 194: 119-124
12. Fong GH, Rossant J,Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70
13. Heldin CH, Westermark B. Mechanism of action and in vivo role of plateletderived growth factor. Physiol Rev 1999; 79: 1283-1316
14. Bhardwaj B, Klassen J, Cossette N, et al. Localization of platelet-derived growth factor b receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996; 2: 773-782
15. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGFsignaling enforces tumor vessel regression by interferingwith pericytemediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338-340
16. PapaetisGS, SyrigosKN. Targeted therapy for gastrointestinal stromal tumors: Current status and future perspectives. Cancer Metastasis Rev. In press
17. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337
18. Papaetis GS, Karapanagiotou LM, Pandha H, et al. Targeted therapy for advanced renal cell cancer: cytokines and beyond. Curr Pharm Des 2008; 14: 2229-2251
19. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367-1373 (Pubitemid 46450424)
20. Prenen H, Cools J,Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622-2627
21. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 597-3605
22. YeeKW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104: 4202-4209
23. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007; 18 Suppl. 10: 3-10
24. Abrams T, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet derived growth factor receptor-b in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478
25. Schmidt CM, Settle SL, Keene JL, et al. Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry. Clin Exp Metastasis 1999; 17: 537-544
26. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766
27. Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225-233
28. Czabanka M, Vinci M, Heppner F, et al. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer 2009; 124: 1293-1300
29. Baratte S, Sarati S, Frigerio E, et al. Quantitation of SU1 1248, an oral multitarget tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semiautomated liquid-liquid extraction. J Chromatogr A 2004; 1024: 87-94
30. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35
31. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007; 27: 1125-1144
32. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006; 17: 353-358
33. Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008; 65: 123-131
34. Washington C, Eli M, Bello C. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects [abstract 553]. Proc Am Soc Clin Oncol 2003; 22: 180
35. Bello C, Houk B, Sherman L. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers [abstract]. J Clin Oncol 2005; 23 Suppl. 16S: 3078
36. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611-1623
37. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005; 31: 536-545
38. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425
39. Bukowski RM. Natural history and therapy of metastatic renal carcinoma: the role of interleukin-2. Cancer 1997; 80: 1198-1220
40. YaoM, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94: 1569-1575
41. Zimmer M, Doucette D, Siddiqui N, et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004; 2: 89-95
42. Rosen L, Mulay M, Long J. Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2003; 22: 765a
43. O'Farell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 5465-5476
44. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-195
45. Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) [abstract 4508]. Proc Am Soc Clin Oncol 2005; 23: 380s
46. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24
47. Motzer RJ,Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524
48. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124 (Pubitemid 46089672)
49. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463
50. Figlin RA, Hutson TE, Tomczak P. Overall survival with sunitinib vs. interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2008; 26 Suppl.: 5024
51. Kollmannsberger CK, Heng DY, Murray N, et al. A population based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone [abstract]. J Clin Oncol 2007; 25 Suppl. 18: 15572
52. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009; 115: 776-783
53. Rini BI, George DJ,Michaelson MD. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma [abstract 4522]. Proc Am Soc Clin Oncol 2006; 24: 222s
54. Redman BG, Hudes GR, Kim ST, et al. Sunitinb in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): updated results from a phase I/II study [abstract]. J Clin Oncol 2008; 26 Suppl.: 16014
55. Ryan CW, Curti BD, Pattee KJ, et al. A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). 2008 Genitourinary Cancers Symposium; 2008 Feb 14-16; San Francisco (CA)
56. Vance V, Amato RJ, Jac J, et al. Phase I study of PEG-intron, sunitinib and tarceva in patients with metastatic renal cell carcer (MRCC) [abstract]. J Clin Oncol 2008; 26 Suppl.: 1465
57. Pandya SS, Mier JW, Cho D, et al. The role of adding gemcitabine at time of sunitinib resistance in patients with metastatic renal cell cancer. 2008 Genitourinary Cancers Symposium; 2008 Feb 14-16; San Francisco (CA)
58. Patel PH, Senico PL, Curiel RE, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 24-27
59. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (9): 1432-1439
60. Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 28-33
61. Haas NB, Uzzo RG. The ASSURE trial-adjuvant sunitinib vs. sorafenib vs. placebo in patients with recsected renal cell carcinoma. US Renal Genito- Urinary Dis 2006; 6: 54-56
62. Biswas S, Kelly J, Eisen T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 2009; 14: 52-59
63. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12
64. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580 (Pubitemid 28067289)
65. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710
66. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006; 59: 557-563
67. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation of Treatment and Research of Cancer - Italian Sarcoma Group - Australasian Gastrointestinal Trials Group Study. J Clin Oncol 2005; 23: 5795-5804
68. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743-1749
69. Heinrichm MC, Maki R, Corless CL. Sunitinib (SU) response in imatinibresistant (IM-R) GIST correlates with KIT and PDGFR mutation status. 42nd Annual Meeting of the American Society for Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
70. Morgan JA, Demetri GD, Fletcher JA. Durable responses to SU11248 (sunitinib malate) are observed across all genotypes of imatinib mesylateresistant GIST. 17th International Congress on Anti Cancer Treatment; 2006 Jan 30-Feb 2; Paris
71. Maki RG, Fletcher JA, Heinrich MC. SU11248 in patients with imatinibresistant GIST: results from a continuation trial. American Society of Clinical Oncology. 41st Annual Meeting; 2005 May 13-17; Orlando (FL)
72. Liegl B, Fletcher JA, Corless CL. Correlation between KIT mutations and sunitinib (SU) resistance in GIST [abstract 92]. Program and abstracts of the 2008 American Society of Clinical Oncology Gastrointestinal Cancer Symposium; 2008 Jan 25-27: Orlando (FL)
73. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338
74. Judson I, Casali P, Garret C. Updated results from a phase III trial of sunitinib in advanced gastrointestinal stromal tumors (GIST) [abstract]. Ann Oncol 2006; 17 Suppl. 9: 962
75. Casali PG, Garret CR, Blackstein ME. Updated results from a phase III trial of sunitinib inGIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. 42nd Annual Meeting of the American Society for Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
76. George S, Blay JY, Casali PG. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis [abstract 10554]. J Clin Oncol 2008; 26: 1530
77. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790-800
78. Yao DF, Wu XH, Zhu Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 220-226
79. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor and angiogenin in patients with respectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355-362
80. Zhang T, Sun HC, Xu Y, et al. Overexpression of platelet-derived growth factor receptor-a in endothelial cells of hepatocellular carcinoma associated with high metastatic poptential. Clin Cancer Res 2005; 11: 8557-8563
81. Zhu AX, Sahani DV, di Tomaso E, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary phase II study. J Clin Oncol (Meeting Abstracts) 2008; 26: 4521
82. Faivre S, DePrimo S, Cheng AL. Correlation of outcome and tumor imaging parameters with circulating biomarkers of sunitinib malate in patients with unresectable hepatocellular carcinoma. 33rd ESMO Congress; 2008 Sep 12-16; Stockholm
83. La Rossa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic feature.HumPathol 2003; 34: 18-27
84. Chaudhry A, Papanicolaou V, Oberg K, et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992; 52: 1006-1012
85. Koch CA, Gimm O, Vortmeyer AO, et al. Does the expression of c-kit (CD- 117) in neuroendocrine tumors represent a target of therapy? AnnN Y Acad Sci 2006; 1073: 517-526
86. Kulke MH, Lenz HJ,Meropol NJ, et al. Activity of sunitinib in patients with advanced neurondocrine tumors. J Clin Oncol 2008; 26: 3403-3410
87. Bajetta E, Guadalupi V, Procopio G. Activity of sunitinib in patients with advanced neurondocrine tumors. J Clin Oncol 2009; 27: 319-20; author reply 320
88. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006; 5: 1280-1289
89. Socinski MA, Novello S, Sanchez JM. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. J Clin Oncol 2006 ASCO Ann Meet Proc Pt I 2006; 24 (18 Suppl. Jun 20): 7001
90. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-656
91. Brahmer JR, Govindan R, Novello S. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 2006 ASCO Ann Meet Proc Pt I 2006; 25 (18 Suppl. Jun 20): 7542
92. Gridelli C, Maione P, RossiA, et al. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther 2009; 9: 115-124
93. Jennbacken K, Vallbo C, Wang W, et al. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65: 110-116
94. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936 (Pubitemid 32994827)
95. Hofer MD, Fecko A, Shen R, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004; 6: 503-512
96. Cumashi A, Tinari N, Rossi C, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008; 270 (2): 229-233
97. Guerin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel: a new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008; 134: 51-57
98. Sonpavde G, Hutson TE, Berry WR, et al. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer 2008; 6: 134-137
99. Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 4793-4799
100. Fenner MH, Beutel G, Grunwald V. Targeted therapies for patientswith germ cell tumors. Expert Opin Investig Drugs 2008; 17: 511-522
101. Dawson SJ, Conus NM, Toner GC, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008; 9: 547-552
102. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816
103. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660-664
104. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83
105. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92: 3531-3534
106. Wolter P, Stefan C, Decallonne B. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer [abstract]. J Clin Oncol 2008; 26 Suppl.: 5126
107. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24: 1329-1331
108. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-1369
109. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572
110. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20 (5): 807-815
111. Kollmannsberger C, Soulieres D, Wong R, et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1 (2 Suppl.): S41-54
112. Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies formetastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-1096
113. Telli ML, Witteles RM, Fisher GA. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. 2008 American Society of Clinical Oncology Genitourinary Cancers Symposium; 2008 Feb 14-16; San Francisco (CA)
114. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-5212
115. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019
116. Chu D, Lacouture ME, Weiner M, et al. Risk of hand-foot skin reaction with multitargeted kinase inhibitor sunitinib in patients with renal cell and nonrenal cell carcinoma: a meta-analysis. Clin Genitour Cancer 2009; 7: 11-19
117. Botchkareva NV, Khlgatian M, Longley BJ, et al. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 2001; 15: 645-658
118. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917-930
119. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib [letter]. J Clin Oncol 2007; 25: 3559 (Pubitemid 47310905)
120. Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis 2009; 12 (1): 13-16
121. Syrigos KN, Zalonis A, Kotteas E, et al. Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev 2008; 27: 273-288
122. Strimpakos AS, Karapanagiotou EM, Saif WM, et al. The role of m TOR in themanagement of solid tumors: an overview. Cancer Treat Rev 2009; 35 (2): 148-159
123. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 27: 495-522